Print

Alkermes plc (ALKS) Release: New Long-Term Data on VIVITROL┬« Showed Sustained Efficacy and Safety over 18 Months of Treatment  
11/9/2011 7:15:01 AM

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today presented positive results from a long-term study of VIVITROL® (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV. Results from the one-year, open-label extension of the six-month pivotal study showed sustained efficacy of VIVITROL, as measured by the number of opioid-free urine screens, in patients who received VIVITROL, in combination with psychosocial treatment, for a total of 18 months of treatment. Additionally, all safety events observed during the open-label extension were consistent with those set forth in the approved product labeling.
//-->